These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 38702019)

  • 1. Photo-regulated PROTACs: A novel tool for temporal control of targeted protein degradation.
    Xu H; Ohoka N; Inoue T; Yokoo H; Demizu Y
    Bioorg Med Chem Lett; 2024 Jul; 107():129778. PubMed ID: 38702019
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In situ albumin-binding and esterase-specifically cleaved BRD4-degrading PROTAC for targeted cancer therapy.
    Cho H; Jeon SI; Shim MK; Ahn CH; Kim K
    Biomaterials; 2023 Apr; 295():122038. PubMed ID: 36787659
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PROTACs: Emerging Targeted Protein Degradation Approaches for Advanced Druggable Strategies.
    Sincere NI; Anand K; Ashique S; Yang J; You C
    Molecules; 2023 May; 28(10):. PubMed ID: 37241755
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effective degradation of EGFR
    Qu X; Liu H; Song X; Sun N; Zhong H; Qiu X; Yang X; Jiang B
    Eur J Med Chem; 2021 Jun; 218():113328. PubMed ID: 33773286
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of a selective BRD4 PROTAC with potent antiproliferative effects in AR-positive prostate cancer based on a dual BET/PLK1 inhibitor.
    Hu R; Wang WL; Yang YY; Hu XT; Wang QW; Zuo WQ; Xu Y; Feng Q; Wang NY
    Eur J Med Chem; 2022 Jan; 227():113922. PubMed ID: 34700270
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antibody-PROTAC Conjugates Enable HER2-Dependent Targeted Protein Degradation of BRD4.
    Maneiro MA; Forte N; Shchepinova MM; Kounde CS; Chudasama V; Baker JR; Tate EW
    ACS Chem Biol; 2020 Jun; 15(6):1306-1312. PubMed ID: 32338867
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Near-Infrared-Activatable PROTAC Nanocages for Controllable Target Protein Degradation and On-Demand Antitumor Therapy.
    He Q; Zhou L; Yu D; Zhu R; Chen Y; Song M; Liu X; Liao Y; Ding T; Fan W; Yu W
    J Med Chem; 2023 Aug; 66(15):10458-10472. PubMed ID: 37279091
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expansion of targeted degradation by Gilteritinib-Warheaded PROTACs to ALK fusion proteins.
    Yokoo H; Tsuji G; Inoue T; Naito M; Demizu Y; Ohoka N
    Bioorg Chem; 2024 Apr; 145():107204. PubMed ID: 38377822
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Alkenyl oxindole is a novel PROTAC moiety that recruits the CRL4DCAF11 E3 ubiquitin ligase complex for targeted protein degradation.
    Wang Y; Wei T; Zhao M; Huang A; Sun F; Chen L; Lin R; Xie Y; Zhang M; Xu S; Sun Z; Hong L; Wang R; Tian R; Li G
    PLoS Biol; 2024 May; 22(5):e3002550. PubMed ID: 38768083
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Delivering on Cell-Selective Protein Degradation Using Chemically Tailored PROTACs.
    Yao R; Luo T; Wang M
    Chembiochem; 2023 Oct; 24(19):e202300413. PubMed ID: 37496112
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hydrogen Peroxide-Inducible PROTACs for Targeted Protein Degradation in Cancer Cells.
    Yu D; Fan H; Zhou Z; Zhang Y; Sun J; Wang L; Jia Y; Tian J; Campbell A; Mi W; Sun H
    Chembiochem; 2023 Sep; 24(17):e202300422. PubMed ID: 37462478
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tumor-targeted PROTAC prodrug nanoplatform enables precise protein degradation and combination cancer therapy.
    Zou ZF; Yang L; Nie HJ; Gao J; Lei SM; Lai Y; Zhang F; Wagner E; Yu HJ; Chen XH; Xu ZA
    Acta Pharmacol Sin; 2024 Aug; 45(8):1740-1751. PubMed ID: 38609561
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Induced degradation of proteins by PROTACs and other strategies: towards promising drugs].
    Reboud-Ravaux M
    Biol Aujourdhui; 2021; 215(1-2):25-43. PubMed ID: 34397373
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Radiotherapy-Triggered Proteolysis Targeting Chimera Prodrug Activation in Tumors.
    Yang C; Yang Y; Li Y; Ni Q; Li J
    J Am Chem Soc; 2023 Jan; 145(1):385-391. PubMed ID: 36542856
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Enhanced Tumor Targeting and Penetration of Proteolysis-Targeting Chimeras through iRGD Peptide Conjugation: A Strategy for Precise Protein Degradation in Breast Cancer.
    He S; Fang Y; Wu M; Zhang P; Gao F; Hu H; Sheng C; Dong G
    J Med Chem; 2023 Dec; 66(24):16828-16842. PubMed ID: 38055861
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synthesis, SAR, and application of JQ1 analogs as PROTACs for cancer therapy.
    De S; Sahu R; Palei S; Narayan Nanda L
    Bioorg Med Chem; 2024 Oct; 112():117875. PubMed ID: 39178586
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Early evaluation of opportunities in oral delivery of PROTACs to overcome their molecular challenges.
    Yang W; Saboo S; Zhou L; Askin S; Bak A
    Drug Discov Today; 2024 Feb; 29(2):103865. PubMed ID: 38154757
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cancer Selective Target Degradation by Folate-Caged PROTACs.
    Liu J; Chen H; Liu Y; Shen Y; Meng F; Kaniskan HÜ; Jin J; Wei W
    J Am Chem Soc; 2021 May; 143(19):7380-7387. PubMed ID: 33970635
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Selective degradation of BRD4 suppresses lung cancer cell proliferation using GSH-responsive PROTAC precursors.
    Fan H; Zhou Z; Yu D; Sun J; Wang L; Jia Y; Tian J; Mi W; Sun H
    Bioorg Chem; 2023 Nov; 140():106793. PubMed ID: 37683536
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Light-Induced Protein Degradation with Photocaged PROTACs.
    Xue G; Wang K; Zhou D; Zhong H; Pan Z
    J Am Chem Soc; 2019 Nov; 141(46):18370-18374. PubMed ID: 31566962
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.